TSNDF · TerrAscend Corp.
Income-statement, balance-sheet and cash-flow figures extracted from the company's SEC filings — 10-K annual and 10-Q quarterly reports — and standardised for comparison across periods.
Chart any reported metric, KPI or segment over time — the full statement history lives here
| Line Item | TTM | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 |
|---|---|---|---|---|---|---|---|
| $263.91M | $260.56M | $268.08M | $250.51M | $247.83M | $194.21M | $132.15M | |
| $124.65M | $124.23M | $132.21M | $112.49M | $146.33M | $81.71M | $46.46M | |
| $139.26M | $136.32M | $135.87M | $138.02M | $101.5M | $112.5M | $85.69M | |
| — | 52.32% | 50.68% | 55.09% | 40.96% | 57.93% | 64.84% | |
| — | — | — | — | — | — | $136K | |
| — | — | — | $9.66M | $10.32M | $1.86M | $1.67M | |
| $88.46M | $86.24M | $90.62M | $83.54M | $115.59M | $75.11M | $60.76M | |
| — | — | — | $115.19M | $115.59M | $75.11M | $60.76M | |
| $6.71M | $6.47M | $6.23M | $7.52M | $12.58M | $6.65M | $5.41M | |
| $5.68M | $5.42M | $5.07M | $5.76M | $9.66M | $5.53M | $3.89M | |
| $96.82M | $94.3M | $96.95M | $108.28M | $437.42M | $89.59M | $65.13M | |
| $42.44M | $42.02M | $38.92M | $29.74M | -$335.92M | $22.91M | $20.56M | |
| — | 16.13% | 14.52% | 11.87% | -135.54% | 11.8% | 15.56% | |
| $48.13M | $47.45M | $44M | $35.49M | -$326.26M | $28.44M | $24.44M | |
| $29.82M | $28.83M | $27.5M | $31.1M | — | — | — | |
| $1.55M | $888K | $851K | -$800K | $206K | $230K | -$393K | |
| -$901K | -$1.37M | -$238K | -$2.6M | $43K | $6.19M | $533K | |
| $3.89M | $4.98M | $4.24M | -$4.24M | -$310.19M | $44.53M | -$116.85M | |
| $31.2M | $29.47M | $25.13M | $23.39M | -$10.78M | $28.88M | $10.77M | |
| -$37.01M | -$81.33M | -$72.67M | -$86.73M | -$325.35M | $6.14M | -$142.26M | |
| — | -31.21% | -27.11% | -34.62% | -131.28% | 3.16% | -107.65% | |
| — | $4.9M | $7.56M | $8.82M | $4.56M | $3.02M | — | |
| -$41.06M | -$87.25M | -$79.02M | -$95.83M | -$330.65M | $9.6M | -$142.08M | |
| USD/shares | — | -$0.29 | -$0.28 | -$0.34 | -$1.35 | $0.02 | -$1.03 |
| USD/shares | — | -$0.29 | -$0.28 | -$0.34 | -$1.35 | $0.01 | -$1.03 |
| shares | — | 301.08M | 291.51M | 279.29M | 244.35M | 181.06M | 149.74M |
| shares | — | 301.08M | 291.51M | 279.29M | 244.35M | 208.71M | 149.74M |
Capital Returned to Shareholders
Cash spent on share repurchases and dividends per fiscal year, as reported on the cash-flow statement. Across FY2024–FY2025: $625K in buybacks.
Price & Valuation
Multiples computed on the strict TTM/EV methodology — today's snapshot against peers, and each ratio recomputed as of past filing dates.
Valuation
Peer medians compare against the 56 similar-size Drug Manufacturers - Specialty & Generic companies (of 104 listed).
Valuation over time computed as of each quarter's filing date
Revenue Breakdown
Annual revenue as the company disaggregates it in its own XBRL filings. Years a component wasn't reported show a dash.
Share mode is each component's slice of the reported components that year — issuers rarely tag every revenue dollar, so slices need not sum to total revenue.
By Geography (USD)
| Component | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 |
|---|---|---|---|---|---|---|
| Canada | $847,000 | $1,042,000 | $925,000 | — | — | — |
| United States | — | — | — | $247,829,000 | $194,210,000 | $132,152,000 |